U.S. Markets open in 1 hr 18 mins

Why This Biotech's Approved Gene Therapy Won't Launch Until 2020

ALLISON GATLIN
Why This Biotech's Approved Gene Therapy Won't Launch Until 2020

Bluebird Bio stock dipped Tuesday after an analyst noted manufacturing hiccups will prevent the biotech company from selling its gene therapy in Europe and the U.S. until 2020 and 2021, respectively.